Beyond Buzzwords in Longevity Investing

LongeVC's Sergey Jakimov and Artem Trotsyuk discuss pragmatic longevity investing, emphasizing the importance of targeting specific age-related diseases rather than pursuing aging as an abstract concept. They highlight the need for data-backed approaches, measurable endpoints, and adherence to FDA regulatory paths, cautioning against hype and nutraceuticals without scientific validation. The conversation explores how longevity companies should focus on specific disease indications to demonstrate efficacy before claiming broader health benefits, using GLPs as an example of a drug with specific benefits that has shown wider health advantages. They also touch on the necessity of realistic expectations from founders regarding timelines, regulatory hurdles, and business development in the biotech industry.